Kairos Pharma (KAPA) Convertible Debt (2023)
Kairos Pharma's (KAPA) quarterly Convertible Debt came in at $638000.0 in Q4 2023.
Kairos Pharma (KAPA) Convertible Debt (2023) Analysis & Trends
Kairos Pharma (KAPA) has 1 years of Convertible Debt data on file, last reported at $638000.0 in Q4 2023.
- Quarterly Convertible Debt changed N/A year-over-year to $638000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $638000.0 (changed N/A YoY) and the FY2023 annual result came in at $638000.0, changed N/A from the prior year.
- Convertible Debt was little changed at $638000.0 in Q4 2023.
- In the past five years, Convertible Debt ranged from a high of $638000.0 in Q4 2023 to a low of $638000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.75 Bn | 130.90 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.96 Bn | 77.96 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn |
| 4 | Moderna | 56.33 Bn | 51.19 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.56 Bn | 28.25 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - |
| 10 | Kairos Pharma | 5.38 Mn | 46,756.81 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 638,000.00 |